Dosage regimes for the administration of an anti-CD19 ADC
US11938192B2 · kind B2 · utility
0Cited by
87References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 18, 2022 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | Mar 18, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.